首页 | 本学科首页   官方微博 | 高级检索  
     


The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial
Authors:Phil McEwan PhD  Angharad R. Morgan PhD  Rebecca Boyce MSc  Klas Bergenheim PhD  Ingrid A.M. Gause-Nilsson MD  Deepak L. Bhatt MD  Lawrence A. Leiter MD  Peter A. Johansson MSc  Ofri Mosenzon MD  Avivit Cahn MD  John P.H. Wilding MD
Affiliation:1. Health Economics and Outcomes Research Ltd, Cardiff, UK;2. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden;3. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;4. Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;5. Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;6. University of Liverpool, Liverpool, UK
Abstract:
Keywords:cost-effectiveness  dapagliflozin  SGLT2 inhibitor  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号